ONCIMMUNE LEADING EARLY CANCER DETECTION
 
ONCIMMUNE LEADING EARLY CANCER DETECTION

EarlyCDT-Lung test results can shift the assessment of malignancy risk of a lung nodule to Intervention risk level (>65%)1

  • For Intermediate (10% – 65%) risk nodules, a High Level EarlyCDT-Lung result shifts ALL nodules to Intervention risk (> 65%)
  • A Moderate Level EarlyCDT-Lung result adds more than 25% risk of malignancy and will shift some nodules from Intermediate to Intervention risk level
  • A ‘No Significant Level of Autoantibodies Detected’ EarlyCDT-Lung result does not change the patient’s overall risk of lung cancer, for it is not a rule out test. With this result, clinicians should continue with their previously selected treatment pathway for the patient. This result delivers additional information to clinicians, which can add confidence that this pathway is correct. This can reduce patients’ anxiety, particularly if the next steps are “watchful waiting”

1Tumor-Associated Autoantibodies: Re-Optimization of EarlyCDT-Lung Diagnostic Performance and Its Application to Indeterminate Pulmonary Nodules. Healey GF, Macdonald IK, Reynolds C, Allen J, Murray A. J Cancer Therapy 2017; doi: 10.4236/jct.2017.85043

PLEASE READ THE FOLLOWING STATEMENT CAREFULLY

Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).

These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.

By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.

Please click on the button below to confirm that you have read, understood and agree with the disclaimer above.

Yes, I accept No, I don't accept